STORM Therapeutics is a cutting-edge biotechnology company based in Cambridge, UK, specializing in RNA epigenetics. With a focus on developing small molecule inhibitors of RNA-modifying enzymes, STORM is at the forefront of pioneering therapies for cancer treatment. Their innovative approach harnesses the power of RNA epigenetics to create novel drug candidates for various diseases, including oncology, inflammation, viral infections, and CNS conditions.

The company's groundbreaking research and RNA analytics platform have identified over 150 RNA modifications and approximately 300 RNA modifying enzymes, opening up exciting new therapeutic possibilities. Notably, STORM's flagship product, the METTL3 inhibitor STC-15, has become the first-ever RNA modifying enzyme inhibitor to enter clinical evaluation in humans. It recently received IND approval and commenced a Phase 1 clinical study for cancer patients in November 2022.

Recognized as one of the industry's most innovative biotechnology companies, STORM was included in Fierce Biotech's prestigious Fierce 15 list for 2022. The company boasts a highly skilled R&D team operating in state-of-the-art laboratories on the Babraham Research Campus. Combining in-house research with strategic collaborations, including partnerships with high-quality CRO partners like Evotec, STORM ensures a cost-efficient and flexible drug development model.

As a pioneering force in the field of RNA epigenetics, STORM Therapeutics is poised to revolutionize the future of healthcare with its groundbreaking therapies and unrivaled expertise